Is Edwards Lifesciences (NYSE:EW) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Edwards Lifesciences at current levels.
TAVI growth is slowing, but the tricuspid and mitral businesses are where the next leg of value gets built.
Where EW is headed
By mid-2028, Edwards looks like a different company than the one Wall Street has been trading since the COVID-era SAPIEN boom. The aortic franchise (still the cash engine at roughly $4.5B in annual sales) becomes the boring, reliable backbone. The interesting story sits in TMTT (Transcatheter Mitral and Tricuspid Therapies), which scales from a $400M curiosity in 2025 to something pushing $1.5B by 2028 as EVOQUE becomes the default tricuspid replacement and PASCAL keeps taking share from Abbott's MitraClip in the mitral repair market. That's not a footnote. That's a second growth engine attached to the same sales force, same hospital relationships, same reimbursement infrastructure.
Read the full Compass Direction on EW
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $87.54).
See the full EW analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Edwards Lifesciences (NYSE:EW) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Edwards Lifesciences at current levels. TAVI growth is slowing, but the tricuspid and mitral businesses are where the next leg of value gets built.
What is EW's Compass Score?
Edwards Lifesciences scores 48/100 on Alexandria's Compass, placing it in the "Neutral" tier. Scores blend eight factors and update weekly.
What is the price target for EW?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the EW page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.